← Mereo BioPharma Group plc (MREO) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
Mereo BioPharma Group plc (MREO)
Pharmaceutical Preparations · market cap $53M · as of 2026-07-11
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-11-09 (est.)
Earnings
Pipeline
5
programs
Upcoming events
1
next 90d+
Dossier
Ready
cached
Mereo BioPharma Group plc (MREO) is a UK-based specialty pharmaceutical company with 36 employees and a $271M market cap trading at ~$0.34/share. The company operates an entirely Phase 2 pipeline spanning COPD (BCT197, Prednisone), Alpha-1 Antitrypsin Deficiency (Alvelestat), oncology (Etigilimab), and endocrinology (BGS649), with $36.2M cash and approximately 25 months of runway. No late-stage or near-term approval catalysts are visible in the current fact set.
The catalyst path
- 2026-11-09 (est.)Earningsimp 5/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| BCT197 | Phase 2 | Pulmonary Disease, Chronic Obstructive |
| Alvelestat oral tablet - dose 1 | Phase 2 | Alpha 1-Antitrypsin Deficiency |
| Etigilimab | Phase 2 | Solid Tumor, Adult |
| BGS649 | Phase 2 | Hypogonadotropic Hypogonadism |
| Active treatment with a high dose of BGS649 | Phase 2 | Endometriosis |
Price & technical context
3-month
+8.8%
6-month
+12.1%
12-month
-82.0%
52-wk range
$0.24–$2.31
vs 50-day MA
+23.0%
vs 200-day MA
-13.0%
Realized vol
231.4%
Max drawdown
-94.9%
Daily closes through 2026-10-01. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for MREO (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 5 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.